Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative DOI Creative Commons
Erlan Sanchez, Tim Wilkinson, Gillian Coughlan

et al.

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 20(3), P. 1753 - 1770

Published: Dec. 17, 2023

Abstract INTRODUCTION We investigated whether novel plasma biomarkers are associated with cognition, cognitive decline, and functional independence in activities of daily living across within neurodegenerative diseases. METHODS Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau (p‐tau)181 amyloid beta (Aβ) 42/40 were measured using ultra‐sensitive Simoa immunoassays 44 healthy controls 480 participants diagnosed Alzheimer's disease/mild impairment (AD/MCI), Parkinson's disease (PD), frontotemporal dementia (FTD) spectrum disorders, or cerebrovascular (CVD). RESULTS GFAP, NfL, and/or p‐tau181 elevated among all diseases compared to controls, broadly worse baseline performance, greater lower independence. While highly predictive diseases, was more specific the AD/MCI cohort. Sparse associations found FTD CVD cohorts for Aβ . DISCUSSION valuable predictors cognition function common may be useful specialized clinics clinical trials.

Language: Английский

Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population‐based study DOI Creative Commons
Yingjin Zhang, Pâmela C.L. Ferreira, Erin Jacobsen

et al.

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(6), P. 4199 - 4211

Published: May 16, 2024

Plasma biomarkers of Alzheimer's disease and related dementias predict global cognitive performance decline over time; it remains unclear how they associate with changes in different dementia syndromes affecting distinct domains.

Language: Английский

Citations

7
A Cross-Sectional Study of Alzheimer-Related Proteins in Women with Polycystic Ovary Syndrome DOI Open Access
Alexandra E. Butler, Abu Saleh Md Moin, Thozhukat Sathyapalan

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 1158 - 1158

Published: Jan. 18, 2024

Polycystic ovary syndrome (PCOS) is the most common endocrine condition in women of reproductive age, and several risk factors found PCOS are associated with an increased Alzheimer's disease (AD). Proteins AD have been reported to include fibronectin (FN) fragments 3 4 (FN1.3 FN1.4, respectively) ApoE. We hypothesized that Alzheimer-related proteins would be dysregulated because insulin resistance obesity. In this comparative cross-sectional analysis, aptamer-based SomaScan proteomic analysis for detection plasma was undertaken a biobank 143 97 control women. Amyloid precursor protein (APP) (p < 0.05) amyloid P-component (APCS) 0.001) were elevated PCOS, while alpha-synuclein (SNCA) reduced PCOS. Associations protective heat shock (HSPs) showed SNCA positively correlated HSP90 0.0001) HSP60 both Correlations markers inflammation APCS interleukin 6 (IL6) = 0.04), Apolipoprotein (Apo) E3 TNF-alpha 0.02). FN, FN1.3, FN1.4 ApoE all significantly 0.05). An AD-associated pattern addition APP SNCA, which same as type 2 diabetes (T2D) with, additionally, elevation APCS. With biomarker being very similar T2D, where there association between suggests larger prospective cohort studies needed determine if causal AD.

Language: Английский

Citations

6
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease DOI Creative Commons
Viswanath Devanarayan, T. Doherty, Arnaud Charil

et al.

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(8), P. 5617 - 5628

Published: June 28, 2024

Abstract BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and amyloid beta (Aβ) 42/Aβ40 in predicting brain levels measured by positron emission tomography (PET) Centiloid (CL) for Alzheimer's disease (AD) staging screening. METHODS Quantification pTau217R Aβ42/Aβ40 employed immunoprecipitation‐mass spectrometry. CL prediction models were developed on a cohort 904 cognitively unimpaired, preclinical early AD subjects validated two independent cohorts. RESULTS Models integrating outperformed alone, up to 89.1 CL. High area under receiver operating characteristic curve (AUROC) values (89.3% 94.7%) observed across broad range (15 90). Utilizing pTau217R‐based low reduced PET scans 70.5% 78.6%. DISCUSSION effectively predicts levels, surpassing cerebrospinal fluid Aβ42/Aβ40's range. Combining it with enhances sensitivity detection, reducing unnecessary expanding clinical utility. CLINICALTRIALS.GOV IDENTIFIERS NCT02956486 (MissionAD1), NCT03036280 (MissionAD2), NCT04468659 (AHEAD3‐45), NCT03887455 (ClarityAD) Highlights Phosphorylated amyloid‐PET spectrum. Integrating extends upper limit Combined model status high accuracy, especially unimpaired individuals. identifies above or below various thresholds accuracy. significantly reduce 78.6% screening out individuals no/low amyloid.

Language: Английский

Citations

6
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease DOI Creative Commons
Andrea Pilotto,

Nicholas J. Ashton,

Alessandro Lupini

et al.

Journal of Neurology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 9, 2024

Language: Английский

Citations

6
Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative DOI Creative Commons
Erlan Sanchez, Tim Wilkinson, Gillian Coughlan

et al.

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 20(3), P. 1753 - 1770

Published: Dec. 17, 2023

Abstract INTRODUCTION We investigated whether novel plasma biomarkers are associated with cognition, cognitive decline, and functional independence in activities of daily living across within neurodegenerative diseases. METHODS Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau (p‐tau)181 amyloid beta (Aβ) 42/40 were measured using ultra‐sensitive Simoa immunoassays 44 healthy controls 480 participants diagnosed Alzheimer's disease/mild impairment (AD/MCI), Parkinson's disease (PD), frontotemporal dementia (FTD) spectrum disorders, or cerebrovascular (CVD). RESULTS GFAP, NfL, and/or p‐tau181 elevated among all diseases compared to controls, broadly worse baseline performance, greater lower independence. While highly predictive diseases, was more specific the AD/MCI cohort. Sparse associations found FTD CVD cohorts for Aβ . DISCUSSION valuable predictors cognition function common may be useful specialized clinics clinical trials.

Language: Английский

Citations

16